Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PNL012
MIFTS: 57

Penile Cancer

Categories: Cancer diseases, Rare diseases, Reproductive diseases, Skin diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Penile Cancer

About this section

MalaCards integrated aliases for Penile Cancer:

Name: Penile Cancer 12 37 15
Penis Carcinoma 12 15 73
Penile Neoplasms 44 73
Penile Neoplasm 12 15
Malignant Neoplasm of Body of Penis 12
Malignant Neoplasm of Penis 73
Malignant Penile Tumor 12
Carcinoma of Penis 12
Neoplasm of Penis 12
Penile Carcinoma 12
Penile Tumor 12
Penile Ca 12
Ca Penis 12

Classifications:

MalaCards categories:
Global: Cancer diseases Rare diseases
Anatomical: Reproductive diseases Skin diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:11615 DOID:11624 DOID:3449
ICD10 33 C60 C60.2 C60.9
ICD9CM 35 187.3 187.4
MeSH 44 D010412
SNOMED-CT 68 93716006 93954003
KEGG 37 H00025
Sources

Summaries for Penile Cancer

About this section
Disease Ontology : 12 A penile cancer that is located in the skin or tissues of the penis.

MalaCards based summary : Penile Cancer, also known as penis carcinoma, is related to papilloma and in situ carcinoma. An important gene associated with Penile Cancer is CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), and among its related pathways/superpathways are Viral carcinogenesis and PI3K-Akt signaling pathway. The drugs Fentanyl and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include lymph node, skin and lung, and related phenotypes are cardiovascular system and immune system

Wikipedia : 76 Penile cancer is a malignant growth found on the skin or in the tissues of the penis. Around 95% of... more...

Sources

Related Diseases for Penile Cancer

About this section

Diseases in the Penile Cancer family:

Penile Cancer, Adult

Diseases related to Penile Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 191)
# Related Disease Score Top Affiliating Genes
1 papilloma 30.2 CCND1 CDKN2A TP53
2 in situ carcinoma 30.0 CDKN2A EGFR TP53
3 squamous cell carcinoma 30.0 CCND1 CDKN2A EGFR PIK3CA TP53
4 basaloid squamous cell carcinoma 29.9 CDKN2A EGFR TP53
5 anogenital venereal wart 29.9 CDKN2A TP53
6 verrucous carcinoma 29.9 CCND1 CDKN2A TP53
7 bladder cancer 29.6 CCND1 CDKN2A EGFR TP53
8 cervical cancer 29.6 CCND1 CDKN2A PIK3CA TP53
9 adenocarcinoma 29.4 CCND1 CDKN2A EGFR PIK3CA TP53
10 transitional cell carcinoma 29.4 CDKN2A EGFR IFNA2 TP53
11 penile cancer, adult 12.3
12 penis carcinoma in situ 12.2
13 penile cancer, childhood 12.1
14 penis verrucous carcinoma 11.1
15 penis basaloid carcinoma 11.1
16 penis papillary carcinoma 11.1
17 penis sarcoma 11.0
18 penis squamous cell carcinoma 10.4
19 adenocarcinoma of the penis 10.4
20 malignant peritoneal mesothelioma 10.3 CDKN2A EGFR
21 peritoneal mesothelioma 10.3 CDKN2A EGFR
22 anaplastic oligodendroglioma 10.3 CDKN2A EGFR
23 brain ependymoma 10.2 EGFR TP53
24 breast papillomatosis 10.2 CCND1 CDKN2A
25 bladder squamous cell carcinoma 10.2 CDKN2A TP53
26 keratinizing squamous cell carcinoma 10.2 CDKN2A TP53
27 tonsil squamous cell carcinoma 10.2 CCND1 CDKN2A
28 spitz nevus 10.2 CDKN2A TP53
29 bowenoid papulosis 10.2 CCND1 CDKN2A
30 skin carcinoma in situ 10.2 CCND1 CDKN2A
31 bladder carcinoma in situ 10.2 CDKN2A TP53
32 vulva squamous cell carcinoma 10.2 CDKN2A TP53
33 scrotal carcinoma 10.2 CDKN2A TP53
34 endometrial squamous cell carcinoma 10.2 CCND1 CDKN2A
35 nasal cavity adenocarcinoma 10.2 CDKN2A TP53
36 bartholin's gland disease 10.2 CDKN2A TP53
37 megaesophagus 10.2 CDKN2A TP53
38 glycogen-rich clear cell breast carcinoma 10.2 CDKN2A TP53
39 adult hepatocellular carcinoma 10.2 PIK3CA TP53
40 gastric adenosquamous carcinoma 10.2 CDKN2A TP53
41 rare adenocarcinoma of the breast 10.2 PIK3CA TP53
42 malignant spiradenoma 10.2 PIK3CA TP53
43 cervix uteri carcinoma in situ 10.2 CDKN2A TP53
44 non-proliferative fibrocystic change of the breast 10.2 CCND1 TP53
45 uterus carcinoma in situ 10.2 CDKN2A TP53
46 oral leukoplakia 10.2 CDKN2A TP53
47 microglandular adenosis 10.2 EGFR TP53
48 synchronous bilateral breast carcinoma 10.2 CCND1 TP53
49 meningeal melanomatosis 10.2 CDKN2A TP53
50 uterine corpus serous adenocarcinoma 10.2 PIK3CA TP53

Graphical network of the top 20 diseases related to Penile Cancer:



Diseases related to Penile Cancer
Sources

Symptoms & Phenotypes for Penile Cancer

About this section

MGI Mouse Phenotypes related to Penile Cancer:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.92 APP CCND1 CDKN2A CRP EGFR PIK3CA
2 immune system MP:0005387 9.86 APP CCND1 CDKN2A CRP EGFR FAM92A
3 integument MP:0010771 9.7 APP CCND1 CDKN2A EGFR PIK3CA SCN10A
4 neoplasm MP:0002006 9.35 CCND1 CDKN2A EGFR PIK3CA TP53
5 no phenotypic analysis MP:0003012 9.1 APP CDKN2A EGFR PIK3CA SCN10A TP53
Sources

Drugs & Therapeutics for Penile Cancer

About this section

Drugs for Penile Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 98)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
2
Paclitaxel Approved, Vet_approved Phase 3,Phase 2 33069-62-4 36314
3
Mechlorethamine Approved, Investigational Phase 3,Phase 2 51-75-2 4033
4
Ifosfamide Approved Phase 3,Phase 2 3778-73-2 3690
5
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
6 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
7 Cola Phase 3,Phase 2,Phase 1,Not Applicable
8 Liver Extracts Phase 3,Phase 2,Phase 1,Not Applicable
9 Central Nervous System Depressants Phase 3,Phase 2
10 Adjuvants, Anesthesia Phase 3
11 Anesthetics, Intravenous Phase 3
12 Analgesics, Opioid Phase 3
13 Peripheral Nervous System Agents Phase 3,Phase 2
14 Anesthetics, General Phase 3
15 Analgesics Phase 3,Phase 2
16 Narcotics Phase 3
17 Anesthetics Phase 3
18
Isophosphamide mustard Phase 3,Phase 2 0
19 Antineoplastic Agents, Phytogenic Phase 3,Phase 2
20 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
21 Alkylating Agents Phase 3,Phase 2,Phase 1
22 Albumin-Bound Paclitaxel Phase 3,Phase 2
23 Antimitotic Agents Phase 3,Phase 2
24
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
25
Indinavir Approved Phase 2 150378-17-9 5362440
26
Irinotecan Approved, Investigational Phase 2 100286-90-6, 97682-44-5 60838
27
Isotretinoin Approved Phase 2 4759-48-2 5538 5282379
28
Cyclophosphamide Approved, Investigational Phase 1, Phase 2,Phase 2 6055-19-2, 50-18-0 2907
29
Fludarabine Approved Phase 1, Phase 2,Phase 2 75607-67-9, 21679-14-1 30751
30
Aldesleukin Approved Phase 1, Phase 2,Phase 2 85898-30-2, 110942-02-4
31
Vidarabine Approved, Investigational Phase 1, Phase 2,Phase 2 24356-66-9 32326 21704
32
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
33
Pembrolizumab Approved Phase 2 1374853-91-4
34
Nivolumab Approved Phase 1, Phase 2,Phase 2 946414-94-4
35
Daratumumab Approved Phase 1, Phase 2 945721-28-8
36
Valproic Acid Approved, Investigational Phase 2 99-66-1 3121
37
Vinblastine Approved Phase 2 865-21-4 241903 13342
38
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
39
Tretinoin Approved, Investigational, Nutraceutical Phase 2 302-79-4 5538 444795
40
Camptothecin Experimental Phase 2 7689-03-4
41 Anti-HIV Agents Phase 2,Phase 1
42 HIV Protease Inhibitors Phase 2
43 Cytochrome P-450 Enzyme Inhibitors Phase 2
44 Antiviral Agents Phase 2,Phase 1
45 Anti-Infective Agents Phase 2,Phase 1
46 Anti-Retroviral Agents Phase 2,Phase 1
47
protease inhibitors Phase 2
48 Cytochrome P-450 CYP3A Inhibitors Phase 2
49 interferons Phase 2,Phase 1
50 topoisomerase I inhibitors Phase 2

Interventional clinical trials:

(show all 50)
# Name Status NCT ID Phase Drugs
1 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
2 International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study) Recruiting NCT02305654 Phase 3 Paclitaxel;Ifosfamide;Cisplatin
3 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
4 Irinotecan and Cisplatin in Treating Patients With Locally Advanced or Metastatic Penile Cancer Completed NCT00066391 Phase 2 cisplatin;irinotecan hydrochloride
5 Neoadjuvant Chemotherapy for Patients With Squamous Cell Carcinoma of the Penis Completed NCT00512096 Phase 2 Ifosfamide;Paclitaxel (Taxol);Cisplatin
6 A Trial of Cabazitaxel Chemotherapy in Relapsed Locally Advanced &/or Metastatic Carcinoma of the Penis Completed NCT03114254 Phase 2 Cabazitaxel
7 Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males Completed NCT01209325 Phase 2
8 Isotretinoin Plus Interferon in Treating Patients With Recurrent Cancer Completed NCT00002506 Phase 2 isotretinoin
9 T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers Completed NCT02280811 Phase 1, Phase 2 Fludarabine;Cyclophosphamide;Aldesleukin
10 Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers Completed NCT01585428 Phase 2 Fludarabine;Cyclophosphamide;Aldesleukin
11 PEnile Cancer Radio- and Immunotherapy CLinical Exploration Study Recruiting NCT03686332 Phase 2 Arm A: Atezolizumab and Radiotherapy;Arm B: Atezolizumab
12 A Study of Avelumab in Penile Cancer Who Are Unfit for or Have Progressed After Platinum-Based Chemotherapy Recruiting NCT03391479 Phase 2 Avelumab
13 Evaluation of Lymphadenectomy and Chemotherapy TIP on Inguinal Lymph Nodes in Squamous Cell Carcinoma of the Penis (AFU-GETUG 25) Recruiting NCT02817958 Phase 2 Chemotherapie TIP
14 Dacomitinib (PF-00299804) in Advanced/Metastatic Squamous Cell Carcinoma of the Penis Recruiting NCT01728233 Phase 2 Dacomitinib
15 Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma Recruiting NCT02837042 Phase 2 Pembrolizumab
16 An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors Recruiting NCT02488759 Phase 1, Phase 2 Nivolumab;Ipilimumab;Relatlimab;Daratumumab
17 HPV Anti-CD40 RNA Vaccine Recruiting NCT03418480 Phase 1, Phase 2 HPV vaccine
18 M7824 in Subjects With HPV Associated Malignancies Recruiting NCT03427411 Phase 2 M7824
19 DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Participants With Recurrent or Metastatic Human Papillomavirus Associated Cancers Recruiting NCT03439085 Phase 2
20 Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic Recruiting NCT02721732 Phase 2
21 Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors Recruiting NCT03333616 Phase 2 Ipilimumab;Nivolumab
22 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
23 Avelumab With Valproic Acid in Virus-associated Cancer Recruiting NCT03357757 Phase 2 Valproic Acid
24 A Phase II Trial of Vinflunine Chemotherapy in Locally-advanced and Metastatic Carcinoma of the Penis (VinCaP) Active, not recruiting NCT02057913 Phase 2 Vinflunine
25 Maintenance Avelumab Immunotherapy in Patients With Locally Advanced or Metastatic Squamous Cell Penile Carcinoma Not yet recruiting NCT03774901 Phase 2 Avelumab
26 S0224, Docetaxel in Treating Patients With Locally Advanced or Metastatic Penile Cancer (TERMINATED) Terminated NCT00058448 Phase 2 docetaxel
27 Study With Pazopanib and Weekly Paclitaxel in Penile Carcinoma (PAZOPEN-SOGUG) Terminated NCT02279576 Phase 2 Pazopanib;Paclitaxel
28 Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma (PENILANE) Withdrawn NCT02014831 Phase 2 Cetuximab;TIP
29 Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions Unknown status NCT00066404 Phase 1
30 Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer Completed NCT00019110 Phase 1
31 MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma Completed NCT00020579 Phase 1 entinostat
32 Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma Completed NCT00083213 Phase 1
33 Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma Completed NCT00082823 Phase 1
34 Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer Completed NCT00003704 Phase 1 capecitabine
35 Cisplatin-based Chemotherapy Combined With P16_37-63 Peptide Vaccination in Patients With HPV-positive Cancers Completed NCT02526316 Phase 1
36 Cabozantinib-s-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors Recruiting NCT02496208 Phase 1 Cabozantinib S-malate
37 A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies Recruiting NCT02571036 Phase 1 DCC-2618
38 HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA Recruiting NCT02379520 Phase 1 Cytoxan;Fludarabine
39 Characterising Metastatic Penile Cancer Using Molecular Imaging - Hybrid MRI-PET [MRI-PET] Unknown status NCT02104063
40 Videoscopic Versus Open Inguinal Lymphadenectomy for Cancer Completed NCT01526486 Not Applicable
41 Cancer in Patients With Gabapentin (GPRD) Completed NCT01236053 Gabapentin prescriptions
42 Interactive, Health Literacy Promoting Text Messages and HPV Vaccine Completion In Minority Adolescents Completed NCT02236273 Not Applicable
43 OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer Completed NCT00900302
44 Early Intervention vs. Standard Palliative Care in Improving End-of-Life Care in Advanced Cancer Patients Completed NCT00253383 Not Applicable
45 Laser Fluorescence in Cancer Surgical Treatment Recruiting NCT03021200 Not Applicable
46 Development of Diagnostics and Treatment of Urological Cancers Recruiting NCT02994758 Not Applicable
47 Integrated Cancer Repository for Cancer Research Recruiting NCT02012699
48 Pharmacological Penile Rehabilitation in the Preservation of Erectile Function Following Bilateral Nerve-Sparing Radical Prostatectomy Active, not recruiting NCT00955929 Not Applicable Placebo QHS and sildenafil and questionnaires;Sildenafil and questionnaire;Trimix combination (Papavarine 30mg/mL Phentholamine 1mg/mL Prostaglandin E1 10 mcg/mmL) and questionnaires
49 Integrating a Health Information Technology System for Primary and Secondary Cervical Cancer Prevention Enrolling by invitation NCT03346915 Not Applicable
50 Engaging Patients and Providers in Collaborative Communication on HPV Vaccination (EPICC-HPV) Not yet recruiting NCT03267251 Not Applicable

Search NIH Clinical Center for Penile Cancer

Cochrane evidence based reviews: penile neoplasms

Sources

Genetic Tests for Penile Cancer

About this section
Sources

Anatomical Context for Penile Cancer

About this section

MalaCards organs/tissues related to Penile Cancer:

41
Lymph Node, Skin, Lung, Brain, Liver, Tonsil, Cervix

The Foundational Model of Anatomy Ontology organs/tissues related to Penile Cancer:

19
The Skin Or Tissues Of The Penis
Sources

Publications for Penile Cancer

About this section

Articles related to Penile Cancer:

(show top 50) (show all 613)
# Title Authors Year
1
Etiological role of human papillomavirus infection in the development of penile cancer. ( 30423461 )
2019
2
Neoadjuvant chemotherapy for penile cancer enabling organ preservation: A case of individualized management for bilateral lymph node metastasis and a bulky primary tumor. ( 30505684 )
2019
3
Penile cancer in MaranhALo, Northeast Brazil: the highest incidence globally? ( 29843769 )
2018
4
The case for nonsurgical therapy of nonmetastatic penile cancer. ( 29950592 )
2018
5
Analysis of the PI3K-AKT-mTOR pathway in penile cancer: evaluation of a therapeutically targetable pathway. ( 29662627 )
2018
6
PIK3CA copy number aberration and activation of the PI3K-AKT-mTOR pathway in varied disease states of penile cancer. ( 29902261 )
2018
7
Molecular characterization and integrative genomic analysis of a panel of newly established penile cancer cell lines. ( 29880898 )
2018
8
Surgical and Oncological Outcomes in Patients After Vascularised Flap Reconstruction for Locoregionally Advanced Penile Cancer. ( 29433986 )
2018
9
The relationship between HPV status and chemoradiotherapy in the locoregional control of penile cancer. ( 29589134 )
2018
10
Penile cancer: Providing patient support. ( 29517510 )
2018
11
Predictors of lymph node status in penile cancer: High-quality administrative datasets give us insight into what's happening in our own backyard. ( 29681264 )
2018
12
Penile cancer: Providing patient support. ( 29561368 )
2018
13
Lymphangioma Circumscriptum Post Radiotherapy for Penile Cancer Treated with COa88 Laser. ( 29782301 )
2018
14
Risks and Benefits of Adjuvant Radiotherapy After Inguinal Lymphadenectomy in Node-positive Penile Cancer: A Systematic Review by the European Association of Urology Penile Cancer Guidelines Panel. ( 29703686 )
2018
15
Prognostic factors in patients with penile cancer after surgical management. ( 29299663 )
2018
16
Thulium-yttrium-aluminium-garnet (Tm:YAG) laser treatment of penile cancer: oncological results, functional outcomes, and quality of life. ( 29197968 )
2018
17
Neo-glans reconstruction for penile cancer: Description of the primary technique using autologous testicular tunica vaginalis graft. ( 29892486 )
2018
18
Comparative Study of Video Endoscopic Inguinal Lymphadenectomy Through a Hypogastric vs Leg Subcutaneous Approach for Penile Cancer. ( 29256632 )
2018
19
Outcomes for Patients with Node-positive Penile Cancer: Impact of Perioperative Systemic Therapies and the Importance of Surgical Intervention. ( 29730019 )
2018
20
Increased Risk of Penile Cancer among Men Working in Agriculture: Some Methodological Issues ( 29801393 )
2018
21
[18F]FDG PET/CT for assessing inguinal lymph nodes in patients with penile cancer - correlation with histopathology after inguinal lymphadenectomy. ( 29536497 )
2018
22
Penile-sparing modalities in the management of low-stage penile cancer. ( 29416267 )
2018
23
Penile cancer sparing surgery: The balance between oncological cure and functional preservation. ( 29306557 )
2018
24
The analysis of human papillomavirus DNA in penile cancer tissue by <i>in situ</i> hybridization. ( 29731917 )
2018
25
Management of Penile Cancer. ( 29942204 )
2018
26
Increased Risk of Penile Cancer among Men Working in Agriculture ( 29374407 )
2018
27
The Role of Human Papilloma Virus in Penile Cancer Prevention and New Therapeutic Agents. ( 30262198 )
2018
28
Insights Into the Management of Lymph Node-Positive Penile Cancer. ( 29494734 )
2018
29
A Comparative study of two types of organ-sparing surgeries for early stage penile cancer: Wide local excision vs partial penectomy. ( 29656798 )
2018
30
Re: Sarah R. Ottenhof, Andrew Leone, Rosa S. Djajadiningrat, et al. Surgical and Oncological Outcomes in Patients After Vascularized Flap Reconstruction for Locoregionally Advanced Penile Cancer. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2018.02.002. ( 29674120 )
2018
31
Prognostic Significance of HPV and p16 Status in Men Diagnosed with Penile Cancer: A Systematic Review and Meta-analysis. ( 29987099 )
2018
32
The Prognostic Value of PIK3CA Copy Number Gain in Penile Cancer. ( 30031830 )
2018
33
Re: Differences in Survival Associated with Lymph Node Dissection in Patients with Invasive Penile Cancer: Results from the National Cancer Database. ( 30037527 )
2018
34
Survival analysis of penile cancer patients treatedat a tertiary oncology hospital. ( 30137117 )
2018
35
Contemporary perceptions of human papillomavirus and penile cancer: Perspectives from a national survey. ( 30138094 )
2018
36
Lymph node yield as a predictor of overall survival following inguinal lymphadenectomy for penile cancer. ( 30143385 )
2018
37
18F-FDG PET/CT as a prognostic factor in penile cancer. ( 30143840 )
2018
38
Health-Related Quality of Life and Sexual Function in Patients Treated for Penile Cancer. ( 30149391 )
2018
39
Immunotherapy for advanced penile cancer - rationale and potential. ( 30166593 )
2018
40
Prognostic Factors of Penile Cancer and the Efficacy of Adjuvant Treatment after Penectomy: Results from a Multi-institution Study. ( 30190657 )
2018
41
Cross-Sectional Patient-Reported Outcome Measuring of Health-Related Quality of Life With Establishment of Cancer- and Treatment-Specific Functional and Symptom Scales in Patients With Penile Cancer. ( 30201215 )
2018
42
New insight in penile cancer. ( 30230297 )
2018
43
The appropriate number of negative lymph nodes dissection for nonmetastatic penile cancer. ( 30255596 )
2018
44
Molecular carcinogenesis in equine penile cancer: A potential animal model for human penile cancer. ( 30270026 )
2018
45
The role of perineural invasion in penile cancer: a meta-analysis and systematic review. ( 30279203 )
2018
46
Detection of micro-metastases by flow cytometry in lymph nodes from patients with penile cancer. ( 30290760 )
2018
47
Current controversies and developments on the role of lymphadenectomy for penile cancer. ( 30301700 )
2018
48
P16INK4a expression in patients with penile cancer. ( 30312320 )
2018
49
Zonal mapping of sentinel lymph nodes in penile cancer patients using fused SPECT/CT imaging and lymphoscintigraphy. ( 30318180 )
2018
50
HPV vaccination is fundamental for reducing or erradicate penile cancer | Opinion: YES. ( 30325594 )
2018
Sources

Variations for Penile Cancer

About this section

Cosmic variations for Penile Cancer:

9 (show top 50) (show all 696)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6949578 TP63 skin,penis,carcinoma,NS c.1922C>T p.A641V 3:189894381-189894381 14
2 COSM10648 TP53 skin,penis,carcinoma,NS c.524G>A p.R175H 17:7675088-7675088 14
3 COSM748 PIK3CA skin,penis,carcinoma,NS c.317G>T p.G106V 3:179199142-179199142 14
4 COSM35624 MYCN skin,penis,carcinoma,NS c.131C>T p.P44L 2:15942195-15942195 14
5 COSM6949581 DOT1L skin,penis,carcinoma,NS c.4292C>T p.A1431V 19:2226813-2226813 14
6 COSM729830 skin,penis,carcinoma,NS c.317G>T p.G106V 3:179199142-179199142 14
7 COSM6949580 skin,penis,carcinoma,NS c.4292C>T p.A1431V 19:2226813-2226813 14
8 COSM99022 skin,penis,carcinoma,NS c.524G>A p.R175H 17:7675088-7675088 14
9 COSM1640851 skin,penis,carcinoma,NS c.524G>A p.R175H 17:7675088-7675088 14
10 COSM99914 skin,penis,carcinoma,NS c.524G>A p.R175H 17:7675088-7675088 14
11 COSM3355994 skin,penis,carcinoma,NS c.524G>A p.R175H 17:7675088-7675088 14
12 COSM99024 skin,penis,carcinoma,NS c.245G>A p.R82H 17:7675088-7675088 14
13 COSM99023 skin,penis,carcinoma,NS c.128G>A p.R43H 17:7675088-7675088 14
14 COSM6949579 skin,penis,carcinoma,NS c.1640C>T p.A547V 3:189894381-189894381 14
15 COSM6932965 ZFHX3 skin,NS,carcinoma,Merkel cell carcinoma c.6172C>T p.P2058S 16:72796510-72796510 7
16 COSM6949138 ZFHX3 skin,NS,carcinoma,Merkel cell carcinoma c.10363C>T p.P3455S 16:72787913-72787913 7
17 COSM6963354 ZFHX3 skin,NS,carcinoma,Merkel cell carcinoma c.6661G>A p.E2221K 16:72796021-72796021 7
18 COSM6935975 YAP1 skin,NS,carcinoma,Merkel cell carcinoma c.380C>T p.S127F 11:102114202-102114202 7
19 COSM6912621 YAP1 skin,NS,carcinoma,Merkel cell carcinoma c.630G>C p.M210I 11:102162513-102162513 7
20 COSM6917521 YAP1 skin,NS,carcinoma,Merkel cell carcinoma c.371G>C p.R124P 11:102114193-102114193 7
21 COSM6932922 VEGFA skin,NS,carcinoma,Merkel cell carcinoma c.855+1G>T p.? 6:43777666-43777666 7
22 COSM6947750 VEGFA skin,NS,carcinoma,Merkel cell carcinoma c.983G>A p.G328E 6:43780752-43780752 7
23 COSM6917817 TSHR skin,NS,carcinoma,Merkel cell carcinoma c.1105G>A p.E369K 14:81143163-81143163 7
24 COSM6917819 TSC2 skin,NS,carcinoma,Merkel cell carcinoma c.2519C>T p.A840V 16:2074363-2074363 7
25 COSM6505726 TSC2 skin,NS,carcinoma,Merkel cell carcinoma c.5213C>T p.S1738F 16:2088279-2088279 7
26 COSM6927263 TSC1 skin,NS,carcinoma,Merkel cell carcinoma c.2204C>T p.A735V 9:132903655-132903655 7
27 COSM6917821 TRAF7 skin,NS,carcinoma,Merkel cell carcinoma c.1871C>T p.S624F 16:2176173-2176173 7
28 COSM6932958 TRAF7 skin,NS,carcinoma,Merkel cell carcinoma c.1601A>T p.Y534F 16:2175597-2175597 7
29 COSM11166 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.406C>T p.Q136* 17:7675206-7675206 7
30 COSM11491 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.743G>C p.R248P 17:7674220-7674220 7
31 COSM10863 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.833C>T p.P278L 17:7673787-7673787 7
32 COSM10939 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.832C>T p.P278S 17:7673788-7673788 7
33 COSM45167 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.402T>A p.F134L 17:7675210-7675210 7
34 COSM78687 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.313G>A p.G105S 17:7676056-7676056 7
35 COSM6920904 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.767C>G p.T256R 17:7674196-7674196 7
36 COSM10794 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.796G>A p.G266R 17:7673824-7673824 7
37 COSM10656 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.742C>T p.R248W 17:7674221-7674221 7
38 COSM44140 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.596G>T p.G199V 17:7674935-7674935 7
39 COSM11073 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.1024C>T p.R342* 17:7670685-7670685 7
40 COSM10654 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.637C>T p.R213* 17:7674894-7674894 7
41 COSM43681 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.647T>G p.V216G 17:7674884-7674884 7
42 COSM10726 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.856G>A p.E286K 17:7673764-7673764 7
43 COSM10660 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.818G>A p.R273H 17:7673802-7673802 7
44 COSM10705 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.586C>T p.R196* 17:7674945-7674945 7
45 COSM11966 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.485T>A p.I162N 17:7675127-7675127 7
46 COSM45114 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.702C>A p.Y234* 17:7674261-7674261 7
47 COSM6947754 TOP1 skin,NS,carcinoma,Merkel cell carcinoma c.763G>A p.E255K 20:41097252-41097252 7
48 COSM6914877 TNFAIP3 skin,NS,carcinoma,Merkel cell carcinoma c.826G>A p.V276I 6:137877096-137877096 7
49 COSM6963332 TCF7L2 skin,NS,carcinoma,Merkel cell carcinoma c.472G>A p.A158T 10:113040115-113040115 7
50 COSM6963336 TCF7L2 skin,NS,carcinoma,Merkel cell carcinoma c.1147G>A p.E383K 10:113152387-113152387 7
Sources

Expression for Penile Cancer

About this section
Search GEO for disease gene expression data for Penile Cancer.
Sources

Pathways for Penile Cancer

About this section

Pathways related to Penile Cancer according to KEGG:

37
# Name Kegg Source Accession
1 Viral carcinogenesis hsa05203

Pathways related to Penile Cancer according to GeneCards Suite gene sharing:

(show all 47)
# Super pathways Score Top Affiliating Genes
1
PI3K-Akt signaling pathway 37
Show member pathways
 12.86 CCND1 EGFR IFNA2 PIK3CA TP53
2
Human cytomegalovirus infection 37
Show member pathways
 12.82 CCND1 CDKN2A EGFR IFNA2 PIK3CA TP53
3
Endometrial cancer 37
Show member pathways
 12.71 CCND1 CDKN2A EGFR PIK3CA TP53
4
Influenza A 37
Show member pathways
 12.67 CCND1 IFNA2 PIK3CA TP53
5
Glioma 37
Show member pathways
 12.59 CCND1 CDKN2A EGFR PIK3CA TP53
6
Gastric cancer 37
Show member pathways
 12.56 CCND1 CDKN2A EGFR PIK3CA TP53
7
Pathways in cancer 37
12.45 CCND1 CDKN2A EGFR IFNA2 PIK3CA TP53
8
Development EGFR signaling pathway 22
Show member pathways
 12.42 CCND1 EGFR PIK3CA TP53
9
ErbB signaling pathway 1 37
Show member pathways
 12.36 CCND1 EGFR PIK3CA TP53
10
Human T-cell leukemia virus 1 infection 37
12.3 CCND1 CDKN2A PIK3CA TP53
11
JAK-STAT signaling pathway (KEGG) 37
Show member pathways
 12.28 CCND1 EGFR IFNA2 PIK3CA
12
MicroRNAs in cancer 37
12.2 CCND1 CDKN2A EGFR PIK3CA TP53
13
Epstein-Barr virus infection 37
12.16 CCND1 IFNA2 PIK3CA TP53
14
Proteoglycans in cancer 37
12.15 CCND1 EGFR PIK3CA TP53
15
Viral carcinogenesis 37
12.14 CCND1 CDKN2A PIK3CA TP53
16
Colorectal Cancer Metastasis 64
12.08 CCND1 EGFR TP53
17
MAPK Signaling: Mitogen Stimulation Pathway 65
Show member pathways
 12.08 CCND1 EGFR PIK3CA TP53
18
Integrated Breast Cancer Pathway 1
12.04 CCND1 EGFR TP53
19
Transcription Androgen Receptor nuclear signaling 22
Show member pathways
 12.01 CCND1 EGFR PIK3CA
20
FoxO signaling pathway 37
Show member pathways
 11.98 CCND1 EGFR PIK3CA
21
Cellular senescence (KEGG) 37
11.98 CCND1 CDKN2A PIK3CA TP53
22
AKT Signaling Pathway 67
11.97 CCND1 EGFR PIK3CA TP53
23
TGF-beta Signaling Pathway (WikiPathways) 1
11.96 APP CCND1 TP53
24
MAPK Pathway 72
Show member pathways
 11.92 EGFR PIK3CA TP53
25
Spinal Cord Injury 1
11.9 CCND1 EGFR TP53
26
Thyroid hormone signaling pathway 37
11.88 CCND1 PIK3CA TP53
27
Hepatitis C 37
11.85 EGFR IFNA2 PIK3CA TP53
28
Jak-Stat Signaling Pathway (sino) 67
11.78 EGFR IFNA2 PIK3CA
29
Small cell lung cancer 37
11.77 CCND1 PIK3CA TP53
30
DNA Damage Response (only ATM dependent) 1
11.77 CCND1 CDKN2A PIK3CA TP53
31
Glioblastoma Multiforme 64
11.71 CCND1 CDKN2A EGFR TP53
32
Platinum drug resistance 37
11.64 CDKN2A PIK3CA TP53
33
p75(NTR)-mediated signaling 1
Show member pathways
 11.58 APP PIK3CA TP53
34
Central carbon metabolism in cancer 37
11.56 EGFR PIK3CA TP53
35
IL-2 Gene Expression in Activated and Quiescent T-Cells 64
Show member pathways
 11.51 CCND1 EGFR PIK3CA
36
Bladder cancer 37 1
11.32 CCND1 CDKN2A EGFR TP53
37
GADD45 Pathway 64
11.21 CCND1 TP53
38
Oncogene Induced Senescence 66
11.2 CDKN2A TP53
39
Trk receptor signaling mediated by PI3K and PLC-gamma 1
11.2 CCND1 PIK3CA
40
a6b1 and a6b4 Integrin signaling 1
11.18 EGFR PIK3CA
41
G-protein signaling_K-RAS regulation pathway 22
11.12 EGFR PIK3CA
42
EGF receptor (ErbB1) signaling pathway 1
11.09 EGFR PIK3CA
43
Inhibition of Ribosome Biogenesis by p14(ARF) 64
11.02 CDKN2A TP53
44
TP53 Network 1
Show member pathways
 11.02 CDKN2A TP53
45
Copper homeostasis 1
10.99 APP CCND1 PIK3CA TP53
46
E-cadherin signaling in keratinocytes 1
10.95 EGFR PIK3CA
47
Photodynamic therapy-induced AP-1 survival signaling. 1
10.63 CCND1 CDKN2A EGFR TP53
Sources

GO Terms for Penile Cancer

About this section

Biological processes related to Penile Cancer according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.81 APP CDKN2A CRP TP53
2 positive regulation of protein phosphorylation GO:0001934 9.71 APP CCND1 EGFR
3 ERBB2 signaling pathway GO:0038128 9.57 EGFR PIK3CA
4 regulation of multicellular organism growth GO:0040014 9.56 APP PIK3CA
5 positive regulation of G2/M transition of mitotic cell cycle GO:0010971 9.55 APP CCND1
6 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.54 APP EGFR PIK3CA
7 regulation of peptidyl-tyrosine phosphorylation GO:0050730 9.52 APP EGFR
8 liver development GO:0001889 9.5 CCND1 EGFR PIK3CA
9 positive regulation of superoxide anion generation GO:0032930 9.49 CRP EGFR
10 replicative senescence GO:0090399 9.48 CDKN2A TP53
11 astrocyte activation GO:0048143 9.46 APP EGFR
12 cytokine-mediated signaling pathway GO:0019221 9.46 CCND1 IFNA2 PIK3CA TP53
13 amyloid fibril formation GO:1990000 9.43 APP CDKN2A
14 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.4 EGFR TP53
15 mitotic G1 DNA damage checkpoint GO:0031571 9.26 CCND1 TP53
16 response to UV-A GO:0070141 8.96 CCND1 EGFR
17 positive regulation of phosphorylation GO:0042327 8.8 APP EGFR IFNA2

Molecular functions related to Penile Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.26 CCND1 CDKN2A EGFR TP53
2 enzyme binding GO:0019899 8.92 APP CCND1 EGFR TP53
Sources

Sources for Penile Cancer

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....